摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

7-n-Pentyl-4-[1-(2-naphthylmethyl)-1,2,5,6-tetrahydro-pyridin-4-yl]-2,2-dimethylchroman-5-ol monohydrate

中文名称
——
中文别名
——
英文名称
7-n-Pentyl-4-[1-(2-naphthylmethyl)-1,2,5,6-tetrahydro-pyridin-4-yl]-2,2-dimethylchroman-5-ol monohydrate
英文别名
7-n-Pentyl-4-[1-(2-naphthylmethyl)-1,2,5,6-tetrahydro-4-pyridyl]-2,2-dimethylchroman-5-ol monohydrate;7-n-Pentyl-4-[1-(2-naphthylmethyl)-1,2,5,6-tetrahydropyrid-4-yl]-2,2-dimethylchroman-5-ol monohydrate;2,2-dimethyl-4-[1-(naphthalen-2-ylmethyl)-3,6-dihydro-2H-pyridin-4-yl]-7-pentyl-3,4-dihydrochromen-5-ol;hydrate
7-n-Pentyl-4-[1-(2-naphthylmethyl)-1,2,5,6-tetrahydro-pyridin-4-yl]-2,2-dimethylchroman-5-ol monohydrate化学式
CAS
——
化学式
C32H39NO2*H2O
mdl
——
分子量
487.682
InChiKey
XVXFOQOEZGHKCO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    6.93
  • 重原子数:
    36
  • 可旋转键数:
    7
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.44
  • 拓扑面积:
    33.7
  • 氢给体数:
    2
  • 氢受体数:
    4

反应信息

  • 作为反应物:
    描述:
    7-n-Pentyl-4-[1-(2-naphthylmethyl)-1,2,5,6-tetrahydro-pyridin-4-yl]-2,2-dimethylchroman-5-ol monohydratesodium acetate乙酸酐 作用下, 以 乙酸乙酯 、 Petroleum ether 为溶剂, 生成 5-acetoxy-2,2-dimethyl-4-[1-(2-naphthylmethyl)-1,2,5,6-tetrahydropyrid-4-yl]-7-n-pentylchroman
    参考文献:
    名称:
    Tetrahydropyrid-4-yl-chroman-5-ol derivatives
    摘要:
    式为:##SPC1## 的化合物及其药学上可接受的无毒盐,其中 R.sub.1 是直链或α-取代甲基或α,α-二取代甲基的5至8个碳原子的烷基,R.sub.5 是氢、R.sub.6 或 CO.R.sub.6,其中 R.sub.6 是1至4个碳原子的烷基或1至4个碳原子的烷基被NR.sub.7 R.sub.8取代,其中 R.sub.7 和 R.sub.8 各自是氢或1至4个碳原子的烷基,或NR.sub.7 R.sub.8 是吡咯烷基、哌啶基或吗啉基,已被发现具有良好的降压活性,同时具有低毒性和基本无催眠副作用。
    公开号:
    US03960880A1
点击查看最新优质反应信息

文献信息

  • Tetrahydropyrid-4-yl-chroman-5-ol derivatives in the treatment of
    申请人:Beecham Group Limited
    公开号:US04011329A1
    公开(公告)日:1977-03-08
    Compounds of the formula: ##STR1## and their pharmaceutically acceptable non-toxic salts, wherein R.sub.1 is alkyl of 5 to 8 carbon atoms which is straight chained or .alpha.-substituted by a methyl group or .alpha.,.alpha.-disubstituted by methyl groups and R.sub.5 is hydrogen, R.sub.6 or CO.R.sub.6 wherein R.sub.6 is alkyl of 1 to 4 carbon atoms or alkyl of 1 to 4 carbon atoms substituted by NR.sub.7 R.sub.8 wherein R.sub.7 and R.sub.8 are each hydrogen or alkyl of 1 to 4 carbon atoms or NR.sub.7 R.sub.8 is pyrrolidino, piperidino or morpholino, have been found to possess good antihypertensive activity while being of low-toxicity and substantially free of sedative side effects.
    公式为:##STR1##及其药学上可接受的无毒盐,其中R.sub.1为5至8个碳原子的直链或.alpha.-取代的甲基或.alpha.,.alpha.-二取代的甲基,R.sub.5为氢,R.sub.6或CO.R.sub.6,其中R.sub.6为1至4个碳原子的烷基或1至4个碳原子的烷基,其被NR.sub.7R.sub.8取代,其中R.sub.7和R.sub.8分别为氢或1至4个碳原子的烷基,或NR.sub.7R.sub.8为吡咯烷基,哌啶基或吗啡环基,已被发现具有良好的降压活性,同时毒性低,基本无镇静副作用。
  • Tetrahydropyrid-4-yl-chroman-5-ol derivatives
    申请人:Beecham Group Limited
    公开号:US03960880A1
    公开(公告)日:1976-06-01
    Compounds of the formula: ##SPC1## And their pharmaceutically acceptable non-toxic salts, wherein R.sub.1 is alkyl of 5 to 8 carbon atoms which is straight chained or .alpha.-substituted by a methyl group or .alpha.,.alpha.-disubstituted by methyl groups and R.sub.5 is hydrogen, R.sub.6 or CO.R.sub.6 wherein R.sub.6 is alkyl of 1 to 4 carbon atoms or alkyl of 1 to 4 carbon atoms substituted by NR.sub.7 R.sub.8 wherein R.sub.7 and R.sub.8 are each hydrogen or alkyl of 1 to 4 carbon atoms or NR.sub.7 R.sub.8 is pyrrolidino, piperidino or morpholino, have been found to possess good antihypertensive activity while being of low-toxicity and substantially free of sedative side effects.
    式为:##SPC1## 的化合物及其药学上可接受的无毒盐,其中 R.sub.1 是直链或α-取代甲基或α,α-二取代甲基的5至8个碳原子的烷基,R.sub.5 是氢、R.sub.6 或 CO.R.sub.6,其中 R.sub.6 是1至4个碳原子的烷基或1至4个碳原子的烷基被NR.sub.7 R.sub.8取代,其中 R.sub.7 和 R.sub.8 各自是氢或1至4个碳原子的烷基,或NR.sub.7 R.sub.8 是吡咯烷基、哌啶基或吗啉基,已被发现具有良好的降压活性,同时具有低毒性和基本无催眠副作用。
查看更多